Integra Lifesciences Holdings (IART) Current Deferred Revenue (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Current Deferred Revenue data on file, last reported at $22.4 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue rose 113.57% year-over-year to $22.4 million; the trailing twelve-month figure through Mar 2026 stood at $22.4 million (up 113.57% YoY), and the FY2025 full-year result was $11.5 million, down 41.72% from the prior year.
• Current Deferred Revenue advanced to $22.4 million in Q1 2026, from $11.5 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $22.4 million in Q1 2026 to a low of $5.3 million in Q1 2022.
• A 5-year average of $11.5 million and a median of $10.5 million in 2025 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue soared 212.43% in 2023 and tumbled 52.9% in 2024, its largest moves.
• Tracing IART's Current Deferred Revenue over 5 years: stood at $7.3 million in 2022, then increased by 17.74% to $8.5 million in 2023, then soared by 130.32% to $19.7 million in 2024, then slumped by 41.72% to $11.5 million in 2025, then jumped by 95.63% to $22.4 million in 2026.
• Business Quant data shows IART's Current Deferred Revenue at $22.4 million in Q1 2026, $11.5 million in Q4 2025, and $11.3 million in Q3 2025.